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Objectives We hypothesized that the expansion of unusual T lymphocytes, CD4CD28null T cells, might represent a key
pathogenetic mechanism of recurrent instability.
Background Clinical presentation of acute coronary syndromes (ACS) is variable. Some patients have recurrent episodes of
instability, despite optimal treatment, whereas others have a single acute event in their life. The CD4CD28null
T cells, with a functional profile that favors vascular injury, have recently been found both in peripheral blood
and in unstable coronary plaques of patients with ACS.
Methods Peripheral blood T cells from 120 consecutive unstable angina (UA) patients were analyzed for the distribution of
T-cell subsets by flow cytometry. Patients were subgrouped according to the occurrence of prior (during the 24
months before the study enrollment) and subsequent (during the 24 months of follow-up) acute coronary events.
For 51 patients, the index event was the first ever (G1); 30 patients had prior events (G2); and 39 patients had
further events at follow-up (death, myocardial infarction, or UA) or both before and after the index event (G3).
Results The CD4CD28null T-cell frequency was higher in G3 than in G2 and G1 (median 9.5% [range 2.4% to 48.0%] vs.
5.1% [range 0.4% to 27.8%] and 2.3% [range 0.2% to 22.8%], respectively; p  0.001). The expansion of
these unusual T lymphocytes was higher in patients with elevated C-reactive protein levels, and it was re-
duced by statin therapy. On multivariate logistic regression analysis, CD4CD28null T-cell frequency was an
independent predictor of future acute coronary events (odds ratio 3.01, 95% confidence interval 1.1 to
8.25; p  0.023).
Conclusions A perturbation of T-cell repertoire is strongly associated with the recurrence of acute coronary events, conceiv-
ably playing a key pathogenetic role. (J Am Coll Cardiol 2007;50:1450–8) © 2007 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.06.040u
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ihe spectrum of clinical presentation of acute coronary
yndromes (ACS) is extremely varied. At one extreme end
f the spectrum, some patients have several acute coronary
vents (either myocardial infarction or unstable angina
UA]) over a period of years, despite the use of the more
dvanced and costly pharmaceutical strategies and invasive
rocedures. At the other end of the spectrum, some patients
ave a single acute event, such as an acute myocardial
nfarction not preceded by anginal symptoms and, after this
vent, remain totally asymptomatic for years (1). The
echanisms of the occasional transition from stable to
rom the *Department of Cardiology and †Flow Cytometry Core Laboratory,
atholic University, Rome, Italy; and the ‡Dipartimento Cardiotoracovascolare,
niversità “Vita e Salute,” Milan, Italy.l
Manuscript received April 5, 2006; revised manuscript received May 3, 2007,
ccepted June 3, 2007.nstable atherosclerosis may not be the same in these 2
xtreme groups (2). We have recently demonstrated that
atients with recurrent acute coronary events have persis-
ently high levels of C-reactive protein (CRP) and enhanced
n vivo and in vitro monocyte response to proinflammatory
timuli (3–6).
See page 1459
Activated inflammatory cells have been found in the
oronary plaques as well as in the peripheral blood of
atients with ACS (7–14). In particular, patients with
A have an increased frequency of CD4 T lymphocytes
haracterized by defective cell surface expression of
D28, a major costimulatory molecule critically involved
n determining the outcome of antigen recognition by T
ymphocytes. CD4CD28null T cells are expanded in the
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October 9, 2007:1450–8 T Cells and Recurrence of Acute Coronary Eventseripheral blood of patients with UA and infiltrate unstable
oronary plaques, where they undergo clonal expansion, prob-
bly triggered by specific antigens (12,13). These cells are
apable of releasing large amounts of interferon (IFN)- and
hey are the dominant population of IFN- producing cells in
he peripheral blood of patients with UA (12). Because of the
ncreased IFN- production, one of their functions is the
ctivation of monocytes and macrophages; indeed, monocytes
rom patients with UA display a molecular fingerprint of
ngoing IFN- stimulation (14). Therefore, CD4CD28null
cells might be involved in the control of plaque-infiltrating
acrophages.
CD4CD28null T cells are distinct from classic helper T
ells in several additional aspects (15). In particular, they
xpress killer immunoglobulin-like receptors, a characteris-
ic of natural killer cells, and have killer cell functions
16,17). Endothelial cells are susceptible to this T-cell–
ediated injury (16). Furthermore, in the presence of CRP
t concentrations frequently found in patients at risk for
oronary events, susceptibility of endothelial cells to T-cell–
ediated cytotoxicity is increased (16).
Therefore, alongside other proinflammatory mechanisms,
e hypothesized that the expansion of T lymphocytes with the
unctional profile of CD4CD28null T cells might represent a
ey pathogenetic mechanism of recurrent instability.
In this study we specifically tested this hypothesis by
easuring CD4CD28null T-cell frequencies and CRP levels
n a consecutive series of unstable and stable angina patients
Figure 1 Patient Selection and Study Design
ACS  acute coronary syndrome; UA  unstable angina.dmitted to our institution. The
A patients were carefully selected
n the basis of the presence or
bsence of recurrent episodes of
nstability (and/or infarction) in
he 24 months before the study
nrollment, and they were fol-
owed for a further period of 24
onths to assess the occurrence of
urther acute coronary events.
oreover, because we have re-
ently observed a relation between
tatin use and frequency of
D4CD28null T cells (18), we also analyzed the influence of
tatin therapy in this cohort of UA patients.
ethods
opulation. The UA patient selection and study design are
resented in Figure 1. We prospectively evaluated 218
onsecutive patients admitted to our coronary care unit
CCU) with a diagnosis of Braunwald class IIIB UA
etween September 2000 and September 2002. Patients
ith UA were considered to have recurrent acute coronary
vents if they had at least 2 CCU admissions with diagnosis
f Braunwald class IIIB UA other than the index event
nd/or myocardial infarction during the 24 months before
he study enrollment. Patients without any previous episode
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CCU  coronary care unit
CRP  C-reactive protein
CSA  chronic stable effort
angina
cTnT  cardiac troponin T
IFN-  interferon-
UA  unstable angina
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T Cells and Recurrence of Acute Coronary Events October 9, 2007:1450–8f UA and/or myocardial infarction were considered to be
atients without recurrent acute coronary events. The UA
atients who did not fulfill the criteria to be considered with
r without recurrent acute coronary events (n  42) were
xcluded from the study. Other exclusion criteria were the
ollowing: 1) evidence of inflammatory or infectious dis-
ases, malignancies, or immunologic or hematologic disor-
ers (n  9); 2) treatment with antiinflammatory drugs
ther then low-dose aspirin (n  6); 3) ejection fraction
40% (n  13); and 4) age 75 years (n  17). The UA
atients were followed for a further period of 24 months
fter enrollment to assess the clinical outcome. Follow-up
isits, consisting of physical examination, a standard 12-lead
lectrocardiogram, and a treadmill stress test were per-
ormed every 6 months. Recurrence of new acute coronary
vents (cardiac death, myocardial infarction, and CCU
dmission for UA) was recorded. For 11 patients, follow-up
ata were not available, and they were excluded from the study.
As a control population, we studied 67 consecutive
atients (54 male, mean age 64  9 years) with chronic
table effort angina (CSA) as first manifestation of ischemic
eart disease lasting2 years, admitted to our institution to
ndergo elective coronary angiography.
Demographic data, classic risk factors, previous revascu-
arization procedures (percutaneous coronary intervention
PCI] or coronary bypass graft surgery), angiographic find-
ngs, left ventricular function, and medical treatments at the
ime of blood sampling were carefully recorded for all
atients. In UA patients, history of previous acute coronary
vents was obtained by patient medical records.
All patients gave their written informed consent. The
thics Committee of the Catholic University of Rome
pproved the study.
tudy design. We compared extreme groups of patients
ith UA (Fig. 1). The UA patients were subgrouped
ccording to the occurrence of prior and further events
uring the 48 months of study observation. For 51 patients,
he index event was the first ever (group 1); 30 patients had
ecurrent instability and/or myocardial infarction during the
revious 24 months, but no further events after the index
ne (group 2); and 39 patients had further events (25
atients were readmitted to the CCU because of UA, 11
atients had an acute myocardial infarction [8 of whom
ere also readmitted because of UA], and 3 patients died)
uring the 24 months of follow-up, and 33 of these 39
atients also had prior events (group 3). Thus, patients in
roup 3 exhibited a strikingly high recurrence of acute
oronary events. Group 4 consisted of 67 patients with CSA
see the preceding section).
lood sampling. Venous blood samples were taken at the
ime of the index event. Total and differential white blood
ell counts and T-cell subset distributions were analyzed on
resh blood samples. Coded plasma and serum samples were
tored at 70°C and analyzed for CRP in a single batch at
he end of the study by laboratory staff unaware of the
linical data. In patients with UA, plasma cardiac troponin w(cTnT) was determined at the time of hospital admission
s a routine measurement by the Department of Clinical
hemistry. All categorization and management of patients
ere independent of these results.
-cell analysis. Total and differential white blood cell
ounts were obtained with a Bayer H-3 hematology ana-
yzer (Bayer Diagnostic Division, Tarrytown, New York)
sing automated cytochemistry in flow.
Heparinized (10 U/ml) whole blood samples were stained
ith fluorescein isothiocyanate-conjugated anti-CD4 (Bec-
on Dickinson, San Jose, California) and phycoerythrin-
onjugated anti-CD28 (Pharmingen, San Diego, Califor-
ia) monoclonal antibodies (mAb) and analyzed by 2-color
ow cytometry on the Coulter Epics XL (Beckman Coulter,
ullerton, California). Nonspecific staining with isotype-
atched control mAb was 1%; the intra- and interassay
ariability was 10%.
The frequencies of total CD4, CD4CD28, and
D4CD28null T cells were determined using WinMDI
oftware (Joseph Trotter, Scripps Research Institute, La
olla, California). A cutoff of 4% CD4CD28null T cells was
hosen to define patients with low or high frequencies of
hese cells, because 4% represented the 90th percentile of
istribution in 100 age-matched healthy subjects (median
.73%, range 0.05% to 4.94%) (15). Moreover, patients
aving 10% CD4CD28null T cells were considered to
ave very high frequencies of these cells, because this value
as more than 10-fold higher than the median value in the
ormal population.
easurements of CRP and cTnT. C-reactive protein was
easured using a high-sensitivity latex-enhanced immu-
onephelometric assay (Latex/ BN II, Dade Behring,
arburg, Germany). The working range of the assay was
.175 to 1,100 mg/l, and the coefficient of variation was
5%. The median normal value for CRP is 0.8 mg/l, with
0% of normal values 3 mg/l. Troponin T was measured
y the third-generation cTnT assay on an Elecsys 2010
Roche Diagnostics, Mannheim, Germany). The minimum
etectable concentration is 0.01 ng/ml, and the 99th per-
entile in healthy individuals is 0.01 ng/ml.
tatistical analysis. Because CRP values and CD4CD28null
-cell frequencies do not follow a normal distribution,
onparametric tests were used: the Kruskal-Wallis test and
he Dunn multiple pairwise comparisons for comparisons
etween groups, and the Spearman rank test for correlation.
he remaining continuous variables were compared using
he 1-way repeated measures analysis of variance with the
onferroni correction for multiple pairwise comparisons as
ppropriate. Proportions were compared using the chi-
quare test. The CRP values and CD4CD28null T-cell
requencies are expressed as median and range; the remain-
ng variables are expressed as mean  SD. Univariate
ogistic regression analysis was used to identify predictors
f long-term outcome in patients with UA after the index
vents. The following clinical and laboratory variables
ere tested: age, gender, classic risk factors, previous PCI
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October 9, 2007:1450–8 T Cells and Recurrence of Acute Coronary Eventsr bypass surgery, history of recurrent acute coronary
vents, left ventricular ejection fraction, multivessel dis-
ase, cTnT levels, statin treatment, CRP levels, and the
ercentage of CD4CD28null T cells. Multivariate logis-
ic regression analysis was then applied to individuate the
ariables independently associated with the outcome.
nly variables with a value of p  0.1 on univariate
nalysis were included in the multivariate model. Event-
ree survival was analyzed by the Kaplan-Meier method,
nd the log rank test was used for comparison among
urves. The interaction between statin treatment and
D4CD28null T-cell frequency on outcome was tested
sing the analysis of covariance. As end points we
linical Characteristics of the Study Populations and Biological Pa
Table 1 Clinical Characteristics of the Study Populations and B
Group 1:
First-Ever Event
Patients, n 51
Age (yrs, mean  SD) 61  11
Gender (M/F) 42/9
Risk factors
Family history of IHD 14 (27)
Hypercholesterolemia 27 (53)
Diabetes 4 (8)
Overweight/obesity 4 (8)
Hypertension 19 (37)
Smoking 30 (59)
Medications
Beta-blockers 32 (63)
ACE inhibitors 17 (33)
Aspirin 43 (84)
Clopidogrel 42 (82)
Statins 27 (53)
Previous history
Unstable angina NA
Myocardial infarction NA
Previous PCI/CABG NA
Multivessel disease 21 (41)
PCI/CABG for the index event 28/14 (55/27)
Follow-up events
Unstable angina NA
Myocardial infarction NA
Death NA
Biologic parameters, median (range)
Troponin T (ng/ml) 0.01 (0.01–0.12)
C-reactive protein (mg/l)* 3.9 (0.6–27.7)
Lymphocyte count (109/l) 1.6 (1.1–2.4)
Total CD4 T-cell frequency (%) 48.8 (12.9–70.2)
CD4CD28null T-cell frequency (%)¶ 2.3 (0.2–22.8)
alues are expressed as n (%) unless otherwise indicated. Group 1: 51 patients with the first-ever ev
he study enrollment; group 3: 39 patients with further events during the 24 months of follow-up (d
hronic stable angina. Because some patients in group 2 and group 3 had both recurrent episodes o
f patients having prior unstable angina and prior myocardial infarction in these 2 groups is highe
4 months of follow-up were also readmitted because of unstable angina, the percentage of patien
s higher than 100%. *p  0.003; Kruskal-Wallis test. †p  0.011 group 3 versus group 1; p  0.
ersus CSA for both C-reactive protein and CD4CD28null T-cell frequency. §p  0.022 group 2 ve
roup 1; p  0.041 group 3 versus group 2; p  0.001 group 3 versus group 4; Dunn multiple co
ACE  angiotensin-converting enzyme; CABG  coronary artery bypass graft surgery; CSA  chronic s
ntervention.onsidered the recurrence of new acute coronary events
cardiac death, myocardial infarction, and CCU admis-
ion for UA) during the 24 months of prospective
ollow-up. Statistical analysis was performed using
igmaStat software (SPSS, Chicago, Illinois). A p value
f 0.05 (2-tailed) was considered to be statistically
ignificant.
esults
D4CD28null T-cell frequencies in different groups.
emographic and clinical data of the study populations and
he biologic parameters measured in the study are reported
ters
ical Parameters
table Angina
Group 2:
vious Events
Group 3:
Further Events
CSA
Group 4
30 39 67
66  8 65  9 64  9
18/12 28/11 54/13
1 (37) 17 (44) 25 (37)
5 (50) 17 (44) 34 (51)
6 (20) 14 (36) 17 (25)
2 (7) 7 (18) 13 (19)
7 (57) 22 (56) 42 (63)
4 (47) 20 (51) 42 (63)
4 (80) 32 (82) 45 (67)
0 (33) 16 (41) 33 (49)
7 (90) 35 (90) 61 (91)
5 (83) 34 (87) 43 (64)
5 (50) 17 (44) 34 (51)
0 (67) 25 (64) NA
1 (70) 20 (51) NA
8 (43/27) 19/8 (49/21) 24/17 (36/25)
4 (47) 19 (49) 38 (57)
1 (57/37) 28/5 (72/13) 25/38 (37/57)
NA 33 (85) NA
NA 11 (28) NA
NA 3 (8) NA
3 (0.01–0.18) 0.03 (0.01–0.21) NA
.6 (0.8–36.3) 9.1 (1.3–53.9)† 2.9 (0.8–6.5)‡
.9 (1.2–3.1) 2 (1.2–3.2) 1.8 (1.4–2.6)
.4 (33.6–77.8) 52.7 (28.3–81.2) 46.3 (16.4–67.3)
.1 (0.4–27.8)§ 9.5 (2.4–48.0) 0.5 (0.02–21.5)‡
up 2: 30 patients with myocardial infarction and/or unstable angina during the 24 months before
yocardial infarction, unstable angina), 33 of them also with prior events; group 4: 67 patients with
le angina andmyocardial infarction during the 24months before study enrollment, the percentage
00%. Similarly, because 8 patients in group 3 who had an acute myocardial infarction during the
g further episodes of unstable angina and a new myocardial infarction during the follow-up period
up 3 versus group 4; Dunn multiple comparisons. ‡p  0.001 unstable angina whole population
up 1; p  0.001 group 2 versus group 4; Dunn multiple comparisons. p  0.001 group 3 versus
ons. ¶p  0.001; Kruskal-Wallis test.rame
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T Cells and Recurrence of Acute Coronary Events October 9, 2007:1450–8n Table 1. No difference was found in the clinical variables,
n lymphocyte count, and in total CD4 T-cell frequency
mong the different groups.
CD4CD28null T-cell frequency was significantly higher
n group 3 than in the other groups. The median frequencies
ranges) of CD4CD28null T cells were 2.3% (0.2% to
2.8%) in group 1 patients, 5.1% (0.4% to 27.8%) in group
patients, 9.5% (2.4% to 48.0%) in group 3 patients, and
.5% (0.02% to 21.5%) in group 4 patients (p 0.001) (Fig.
A, Table 1). A CD4CD28null T-cell frequency of 4%
as found in 18 of the 51 group 1 patients (35%), 17 of 30
roup 2 patients (57%), 30 of 39 group 3 patients (77%),
nd 8 of 67 group 4 patients (12%; p 0.001). Intriguingly,
he difference among groups was almost exclusively due to
he percentage of patients having very high frequencies
10%) of CD4CD28null T cells: 5 of the 51 group 1
atients (10%), 9 of 30 group 2 patients (30%), 20 of 39
roup 3 patients (51%), and 6 of 67 group 4 patients (9%;
 0.001).
We also performed subgroup analysis between groups 2
nd 3 according to the feature of coronary events (UA,
yocardial infarction, or death) experienced earlier or after
he index admission. Within group 2, no difference in
D4CD28null T-cell frequency were observed between
atients (n  9) with a history of UA (7.3%, 0.2% to 48%),
nd patients (n  21) with a history of both UA and
yocardial infarction (6.7%, 0.6% to 36%; p  0.30).
ithin group 3, the percentage of CD4CD28null T cells
as significantly higher in patients with acute myocardial
nfarction or death during the follow-up (n 14) compared
ith patients readmitted to the CCU because of UA (n 
Figure 2 CD4CD28null T-Cell Frequencies in Different Groups
Frequencies of CD4CD28null T cells were determined by 2-color flow-cytometry. (A
both prior and further events during the 48 months of study observation. Group 1:
and/or UA during the 24 months before study enrollment; group 3: 39 patients wi
the majority of whom (85%) also had prior events; group 4: 67 patients with chron
higher in group 3 than in the other groups (p  0.001; Kruskal-Wallis test). (B) Th
or more) during the 24 months before the study enrollment independently of the p
patients with previous events than in 57 patients without previous events (p  0.0
CD4CD28null T-cell frequencies 4% (90th percentile of distribution in 100 age-m
subjects). Blue, green, and red dots indicate patients with CD4CD28null T-cell fre5): 18.2% (4.7% to 48%) versus 5.0% (0.4% to 35%; p 
.027).
In UA patients, we also compared CD4CD28null T-cell
requencies according to the presence or absence of coronary
nstability before the index event independently of the
rospective outcome. The median frequencies (range) of
D4CD28null T cells were 2.5% (0.2% to 26.8%) in 57
atients without previous coronary instability and 5.4%
0.4% to 48.0%) in 63 patients with previous coronary
nstability (p  0.006) (Fig. 2B). Frequencies 4% were
ound in 22 (39%) and 43 (68%) patients, respectively (p 
.001). Very high frequencies (10%) were found in 7
12%) and 27 (43%) patients, respectively (p  0.001). Of
ote, the percentage of patients on statins was similar in the
groups: 31 of 57 (54%) in patients without previous
oronary instability versus 28 of 63 (44%) in patients with
revious coronary instability (p  0.27).
Moreover, CD4CD28null T-cell frequency significantly
ncreased according to the number of acute coronary events
ccurring during the 24 months before the study enroll-
ent, from 2.5% (0.2% to 26.8%) in patients with a single
vent to 14.2% (0.6% to 48.0%) in patients with 4 to 5
vents (p  0.001) (Fig. 3).
D4CD28null T-cell frequencies according to CRP,
TnT, and statin therapy status in patients with UA.
mong the 120 UA patients, 73 (61%) had high levels of
RP (3 mg/l), median value 9.5 mg/l (range 3 to 86.3
g/l), and 47 had low levels of CRP (3 mg/l), median
alue 1.3 mg/l (range 0.6 to 2.9 mg/l).
As shown in Figure 4A, CD4CD28null T cells were
referentially expanded in patients with UA and elevated
unstable angina (UA) patients were subgrouped according to the occurrence of
tients with the first-ever event; group 2: 30 patients with myocardial infarction
er events during the 24 months of follow-up (death, myocardial infarction, UA),
le effort angina (CSA). The CD4CD28null T-cell frequency was significantly
atients were subgrouped according to the occurrence of events (none versus 2
tive outcome. CD4CD28null T-cell frequency was significantly higher in 63
ata are presented as single data points. The dashed lines indicate
d healthy subjects) and 10% (10-fold higher than the median value in healthy
ies 4%, 4% to 10%, and 10%, respectively.) The
51 pa
th furth
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October 9, 2007:1450–8 T Cells and Recurrence of Acute Coronary Eventsevels of CRP (median frequency 8.5%, range 0.2% to 48%).
n contrast, CD4CD28null T cells were infrequent in
atients with UA and low levels of CRP (median frequency
.7%, range 0.2% to 21.9%; p  0.001 vs. UA  high
RP). A high frequency (4%) was found in 67% of UA
atients with high CRP levels and in 32% of UA patients
ith low CRP levels (p  0.001). A very high frequency
10%) was found in 38% of UA with high CRP levels and
n 15% of UA with low CRP levels (p  0.011).
In the overall population including UA and CSA pa-
ients, a statistically significant correlation was found be-
ween CD4CD28null T-cell frequencies and CRP levels
r  0.39; p  0.001) (Fig. 4B).
Although 48 (66%) out of 73 UA patients with high CRP
evels had a high level of cTnT (0.01 ng/ml) during the
rst 24 h after CCU admission, compared with 11 (23%)
Figure 3 CD4
CD28null T-Cell Frequencies
According to the Number of Acute Coronary Events
In patients with unstable angina, CD4CD28null T-cell frequency significantly
increased according to the number of events occurring during the 24 months
before the study enrollment: 1 versus 2 to 3 and 4 to 5 (p  0.001; Kruskal-
Wallis test). Data are presented as in Figure 2.
Figure 4 CD4CD28null T Cells and CRP
(A) CD4CD28null T-cell frequency was significantly higher in patients with unstabl
with UA and low CRP levels (p  0.001). Data are presented as in Figure 2. (B) In
tion was found between CD4CD28null T-cell frequencies and CRP levels (r  0.39ut of 47 UA patients with low CRP levels (p  0.001), no
ifference was found in CD4CD28null T-cell frequency
ccording to cTnT seropositivity. Thus, the median
D4CD28null T-cell frequency was 5.1% (range 0.6% to
8%) in UA patients with positive cTnT and 3.9% (range
.2% to 38.5%) in UA patients with negative cTnT (p 
.40).
A total of 59 patients were treated with statins before the
tudy enrollment (74  28 days): atorvastatin at 20 mg/day
45 patients, 76%), atorvastatin at 40 mg/day (8 patients),
nd pravastatin at 40 mg/day (6 patients). The 59 patients
n statins before the study enrollment were compared with
he 61 patients who never took statins. The percentage of
D4CD28null T cells was significantly lower in patients
n statins (median 2.4%, range 0.2% to 38.5%) than in
atients who never took statins (median 5.9%, range 0.6% to
8.0%; p  0.001). Also, CRP levels were lower in patients
n statins (median 2.4 mg/l, range 0.6 to 37.2 mg/l) than in
atients not on statins (median 7.4 mg/l, range 0.8 to 86.3
g/l; p  0.001).
rognostic significance of CD4CD28null T cells in
atients with UA. Univariate logistic regression analysis
as used to identify predictors of long-term outcome after
he index event. A CD4CD28null T-cell frequency higher
han 4% was the strongest predictor of future acute coronary
vents (odds ratio [OR] 3.73, 95% confidence interval [CI]
.56 to 8.94; p  0.003), followed by history of recurrent
nstability (OR 3.33, 95% CI 1.39 to 7.98; p  0.006),
iabetes (OR 3.13, 95% CI 1.14 to 8.56; p  0.025), CRP
evels (OR 1.78, 95% CI 1.02 to 3.98; p  0.036), and
TnT levels (OR 1.28, 95% CI 0.96 to 2.51; p 0.065). On
ultivariate logistic regression analysis, a history of recur-
ent instability (OR 2.73, 95% CI 1.08 to 6.90; p  0.032)
nd CD4CD28null T-cell frequency (OR 3.01, 95% CI 1.1
o 8.25; p  0.023) were the only variables independently
ssociated with the clinical outcome (Table 2).
na (UA) and elevated C-reactive protein (CRP) levels (3 mg/l) than in patients
verall population including UA and CSA patients, a statistically significant correla-
0.001).e angi
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T Cells and Recurrence of Acute Coronary Events October 9, 2007:1450–8The 24-month survival free of readmission for UA,
yocardial infarction, and death was significantly higher in
atients with a percentage of CD4CD28null T cells 4%
han in patients with CD4CD28null T cells 4% as
ssessed by the log rank test (p  0.004) (Fig. 5).
Finally, the event rate according to CD4CD28null
-cell frequency (4%, 4% to 10%, 10%) and statin
Figure 5 Kaplan-Meier Cumulative Survival Plot
According to CD4CD28null T-Cell Frequency
The 24-month survival free of readmission for unstable angina, myocardial
infarction, and death was significantly higher in patients with a percentage of
CD4CD28null T cells 4% (blue line) than in patients with CD4CD28null T
cells 4% (red line) as assessed by the log rank test (p  0.004).
redictors of Long-Termutcome in Unstabl Angina
Table 2 Predictors of Long-TermOutcome in Unstable Angina
Variable OR (95% CI) p Value
Univariate analysis
Age 1.03 (0.99–1.07) 0.11
Male gender 1.06 (0.78–1.44) 0.68
Family history of IHD 1.74 (0.76–3.99) 0.18
Hypertension 1.5 (0.67–3.41) 0.31
Smoking 1.05 (0.81–1.23) 0.55
Diabetes 3.13 (1.14–8.56) 0.025
Overweight/obesity 2.72 (0.76–9.75) 0.12
Hypercholesterolemia 1.05 (0.91–1.20) 0.51
History of recurrent ACS 3.33 (1.39–7.98) 0.006
Previous PCI/CABG 1.48 (0.61–3.59) 0.38
Multivessel disease 1.00 (0.99–1.02) 0.57
Statin treatment 0.73 (0.32–1.66) 0.45
Troponin T 0.01 ng/ml 1.28 (0.96–2.51) 0.065
hs-CRP 3 mg/l 1.78 (1.02–3.98) 0.036
CD4CD28null T-cell frequency 4% 3.73 (1.56–8.94) 0.003
Multivariate analysis
CD4CD28null T-cell frequency 4% 3.01 (1.1–8.25) 0.023
Previous history of recurrent ACS 2.73 (1.08–6.90) 0.032
Diabetes 2.70 (0.91–7.99) 0.069
hs-CRP 3 mg/l 0.98 (0.37–2.64) 0.18
Troponin T 0.01 ng/ml 1.15 (0.58–2.27) 0.54
CS  acute coronary syndrome; CI  confidence interval; hs-CRP  high-sensitivity C-reactive
rotein; OR  odds ratio; other abbreviations as in Table 1.reatment was 15%, 30%, and 33% in patients treated with
tatins (p  0.58), and 17%, 25%, and 64% in patients who
ever took statins (p  0.003) (Fig. 6). However, no interac-
ion was demonstrated between CD4CD28null T-cell fre-
uency and statin treatment by analysis of covariance.
iscussion
he spectrum of clinical presentations of ACS is extremely
aried. Some patients present recurrent episodes of instabil-
ty (myocardial infarction and/or UA), despite the use of the
ore advanced and costly therapeutic strategies, whereas
thers have a single acute event in their life. The pathoge-
etic mechanisms and/or the specific triggers of the occa-
ional transition from stable to unstable atherosclerosis may
e different in these 2 subsets of patients (1,2).
The present study supports the notion that a perturbation
f the T-cell repertoire may affect the tendency of coronary
nstability to recur. Indeed, in a well-selected population of
atients with recurrent instability, the median frequency of
D28-lacking CD4 T cells was about 4-fold higher than
n patients with UA as first-ever event. A gradient of values
as been observed, with an intermediate value in patients
ith UA and history of recurrent instability and/or myo-
ardial infarction during the previous 24 months but no
urther events after the index admission.
CD4CD28null T-cell expansion in UA was related to
ystemic evidence of inflammation, because significantly
igher frequencies of CD4CD28null T cells were found in
A patients with high CRP levels than in those with low
RP levels. A positive correlation was observed between
D4CD28null T cells and CRP levels. In contrast, no
ifference was found in CD4CD28null T-cell frequencies
ccording to cTnT status, thus making unlikely the influ-
nce of myocardial cell damage per se.
Figure 6 Event Rate According to CD4
CD28null
T-Cell Frequency and Statin Treatment
The event rate, at 24 months of follow-up, according to CD4CD28null T-cell
frequency (4%, 4% to 10%, and 10%) and statin treatment was 15%, 30%,
and 33% in patients treated with statins (p  0.58) and 17%, 25%, and 64%
in patients who never took statins (p  0.003).
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October 9, 2007:1450–8 T Cells and Recurrence of Acute Coronary EventsFinally, as already demonstrated by our group in a
ifferent subset of patients with UA (18), the present study
lso suggests that statin therapy might be able to reduce
D4CD28null T-cell frequency. However, prospective
andomized studies are needed to confirm this novel anti-
nflammatory property of statins and the beneficial effects on
he recurrence of ACS.
ey features of CD4CD28null T cells. CD4CD28null
cells are a population of lymphocytes rarely found in
ealthy individuals (15). The number of these cells increases
ith age and, although mechanisms leading to immunose-
escence are complex, CD28null T cells are the most
onsistent biologic indicators of aging in the immune
ystem (19). Despite the loss of the CD28 molecule, these
ells are functionally active and possess specific immuno-
ogic properties (12,14–17). Disease-associated expansions
f these cells have been reported in inflammatory disorders
uch as rheumatoid arthritis, Wegener’s granulomatosis,
ultiple sclerosis, and ankylosing spondylitis and in chronic
nfections (19). The severity of clinical manifestations of
hese diseases is correlated with the frequency of CD28null
cells. In rheumatoid arthritis, the frequency of
D4CD28null T cells correlates with extra-articular man-
festations and in particular with vasculitic complications
15). Patients with rheumatoid arthritis and persistent
D4CD28null T-cell expansion show signs of atheroscle-
otic vessel damage, thus suggesting that these cells might
lay a pathogenetic role in the excess of cardiovascular
ortality associated with rheumatoid arthritis (20,21).
otential mechanisms of CD4CD28null T-cell expan-
ion. Environmental as well as genetic mechanisms could
nderlie the expansion of CD4CD28null T cells (19). The
xpression of CD28 is regulated by a complex cytokine
etwork. T-cell activation in the presence of the proinflam-
atory cytokine interleukin-12 results in the restoration of
D28 gene transcription and cell surface appearance of a
unctional CD28 molecule on CD4CD28null cells (22),
hereas tumor necrosis factor- has a down-regulatory
ction (23). The defect in CD28 cell surface expression
ight result from chronic exposure to antigens. Therefore,
he expansion of CD4CD28null T cells in UA patients may
eflect a persistent immune response to microorganisms or
utoantigens contained in atherosclerotic plaques as well
s more diffuse to the entire coronary tree or circulating
n peripheral blood. We have previously shown that, in
atients with UA, circulating and coronary plaque-
nfiltrating CD4CD28null T cells are highly oligoclonal,
uggesting ongoing antigenic stimulation (13). Accord-
ngly, Zal et al. (24) have recently demonstrated that the
irculating CD4CD28null T lymphocytes in UA pro-
uce large quantities of IFN- and, consequently, of
roinflammatory cytokines in response to very restricted
ntigenic stimulation.
tudy limitations. Because the goal of this study was to
nvestigate the role of CD4CD28null T cells in recurrent
nstability, we enrolled consecutive patients admitted withA at the two extremes of the spectrum: at one extreme
atients without any history of ischemic heart disease, at the
ther extreme patients who had at least 2 episodes of
oronary instability in the 2 years before admission. There-
ore, the findings of the present study cannot be extrapo-
ated to a general population of patients admitted to CCUs
ith diagnosis of Braunwald class IIIB UA.
Furthermore, our findings on statins come from a retro-
pective analysis; therefore, no final conclusion can be drawn
n the potential novel anti-inflammatory property of statins
o reduce the frequency of CD4CD28null T cells in UA.
Finally, we recognize the limitation of some purely
exploratory” subgroup analyses we performed in the study.
onclusions
n the spectrum of clinical presentations of ACS, some
atients exhibit a strikingly high recurrence of acute coro-
ary events. These patients have a defect in T-cell ho-
eostasis resulting in considerably high frequencies of
D4CD28null T cells, an unusual subset of T lymphocytes
ith functional activities that may predispose to vascular
njury. Patients with UA and frequent recurrence of acute
oronary events have median frequency of CD28-lacking
D4 cells about 4-fold higher than patients with a
rst-ever acute coronary event during 4 years of clinical
bservation, and about 9-fold higher than patients with
SA. Moreover, on multivariate logistic regression analysis,
D4CD28null T-cell frequency was an independent pre-
ictor of future acute coronary events. Our findings might
ot only help to better understand the inflammatory process
nvolved in the pathogenesis of ACS, but they also might
ave clinical relevance. Indeed, our group has recently
emonstrated that statin treatment, as well as a specific
nti–tumor necrosis factor- treatment, is able to modulate
D4CD28null T lymphocytes in UA (18,25).
Further studies are warranted to test the clinical relevance
f our findings and their importance in introducing inno-
ative approaches for prevention and treatment of ACS.
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